Diana L. Farmer
University of California, Davis
269 Papers
2.2K Citations
Diana L. Farmer is an academic researcher from University of California, Davis. The author has contributed to research in topics: Medicine & Fetal surgery. The author has an hindex of 52, co-authored 235 publications. Previous affiliations of Diana L. Farmer include San Joaquin General Hospital & Shriners Hospitals for Children.
Chat about Author
Papers
Fetal Repair of Neural Tube Defects.
TL;DR: In this article , the use of stem cells in fetal repair is investigated to further improve distal motor function in patients with myelomeningocele malformation, which is the most common congenital neurologic defect, and the only nonlethal disease addressed by fetal surgery.
7
Extracorporeal membrane oxygenation as salvage in pediatric surgical emergencies
Diana L. Farmer,Diana L. Farmer,Marc L. Cullen,Marc L. Cullen,Arvin I. Philippart,Arvin I. Philippart,Fredrick E Rector,Fredrick E Rector,Michael D. Klein,Michael D. Klein +9 more
TL;DR: The authors reviewed a 10-year clinical experience with ECMO and its application as salvage therapy in pediatric surgical emergencies and encouraged the authors to expand their indications and to push the "envelope" in offering ECMO to critically ill infants and children with life-threatening organ failure.
7
Extralobar pulmonary sequestration: The importance of intraoperative vigilance
TL;DR: This unique case of an extralobar pulmonary sequestration diagnosed prenatally via ultrasound and then thoracoscopically resected when the infant was 5 months old emphasizes the importance of constant vigilance for aberrant anatomy during resection.
6
Traction Elongation for Treatment of Long-Gap Esophageal Atresia
TL;DR: A novel method for gradual traction elongation for repair of long-gap atresia of the esophagus is described, similar to that of distraction osteogenesis whereby gradual continuous directional forces are applied on tissue for the purposes of lengthening.
6
Cytotoxicity of lymphokine-activated killer cells against human neuroblastoma cells: modulation by neuroblast differentiation.
TL;DR: The potential use of LAK treatment for neuroblastoma, in combination with differentiation agents that do not affect neuroblastomas sensitivities toward LAK cells, is supported, despite the fact that some differentiation agents and endogenous prostaglandins may interfere with LAK activation.
6